Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9386894 | 1.00 | HSD17B10 (0.50) | HSD17B10CTSKSMN1; SMN2LMNAHPGD | |
| SCHEMBL1330352 | 1.00 | HSD17B10 (0.50) | HSD17B10CTSKSMN1; SMN2LMNAHPGD | |
| SCHEMBL29985720 | 0.92 | HSD17B10 (0.49) | HSD17B10CTSKSMN1; SMN2LMNAHPGD | |
| SCHEMBL15447605 | 0.85 | CTSK (0.43) | HSD17B10CTSKSMN1; SMN2LMNAHPGD | |
| SCHEMBL19479525 | 0.85 | CTSK (0.43) | HSD17B10CTSKSMN1; SMN2LMNAHPGD | |
| SCHEMBL12643647 | 0.85 | L3MBTL1 (0.44) | HSD17B10CTSKSMN1; SMN2LMNAMEN1 | |
| SCHEMBL7518566 | 0.83 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2LMNAHPGDMEN1 | |
| SCHEMBL4845470 | 0.81 | FKBP1A (0.45) | HSD17B10CTSKSMN1; SMN2LMNAHPGD | |
| SCHEMBL15443470 | 0.79 | CTSK (0.42) | HSD17B10CTSKSMN1; SMN2HPGDMEN1 | |
| SCHEMBL18562067 | 0.79 | CTSK (0.42) | HSD17B10CTSKSMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688789-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12465643-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250319187-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12409225-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12403196-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255964-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-08-14 | — | — | US | disclosed |
| US-20250242029-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2025-07-31 | — | — | US | disclosed |
| US-20250195662-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-06-19 | — | — | US | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-20250186590-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | disclosed |
| WO-2024211663-A9 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024211663-A1 | CONDENSED MACROCYCLIC COMPOUNDS AS RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2023223057-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | CYPRALIS LIMITED (GB) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023208005-A1 | CYCLIC COMPOUNDS, PREPARATION METHODS AND MEDICINAL USES THEREOF | HANSOH BIO LLC (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4214209-A1 | INDOLE DERIVATIVES AS RAS INHIBITORS IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220105185-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2022-04-07 | — | — | US | disclosed |
| WO-2022060836-A1 | INDOLE DERIVATIVES AS RAS INHIBITORS IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2005028449-A1 | IMPROVED PROCESS FOR THE MANUFACTURE OF 1,2-DISUBSTITUTED HEXAHYDROPYRIDAZINE-3-CARBOXYLIC ACIDS AND ESTERS THEREOF | HONEYWELL SPECIALTY CHEMICALS SEELZE GMBH (DE) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195662-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885 |
| US-20250186590-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885 |
| US-20250319187-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | HSD17B10 4251/4885CTSK 3524/4885SMN1; SMN2 986/4885 |
| US-20250255964-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885 |
| US-11690915-B2 | Ras inhibitors | KRAS, NRAS, HRAS | HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885 |
| US-12403196-B2 | Ras inhibitors | KRAS, NRAS, HRAS | HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885 |
| US-12465643-B2 | Ras inhibitors | KRAS, NRAS, HRAS | HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885 |
| US-20230226186-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885 |
| US-20250242029-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885 |
| US-20220105185-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885 |
| US-12409225-B2 | Ras inhibitors | KRAS, NRAS, HRAS | HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.